scholarly journals Assessment of Malignant Melanoma Risk Factors and Their Attitudes Towards Protection from the Sun in Patients Applying to Family Physician Polyclinics

2017 ◽  
pp. 1-6
Author(s):  
Ezgi Ağadayı ◽  
Aybüke Demir Alsancak ◽  
Duygu Üstünol ◽  
İrfan Şencan ◽  
Hatice Küçükceran ◽  
...  
Keyword(s):  
Risk Factors ◽  
Malignant Melanoma ◽  
Family Physician ◽  
The Sun ◽  
Melanoma Risk

“Thin” Malignant Melanoma: Risk Factors and Clinical Management

1992 ◽  
Vol 28 (1) ◽  
pp. 89-94 ◽  
Author(s):  
Craig L. Slingluff ◽  
Hilliard F. Seigler
Keyword(s):  
Risk Factors ◽  
Malignant Melanoma ◽  
Clinical Management ◽  
Melanoma Risk

scholarly journals Malignant melanoma risk factors by anatomic site: A case-control study and polychotomous logistic regression analysis

1996 ◽  
Vol 67 (5) ◽  
pp. 636-643 ◽  
Author(s):  
Ya-Ting Chen ◽  
Robert Dubrow ◽  
Theodore R. Holford ◽  
Tongzhang Zheng ◽  
Raymond L. Barnhill ◽  
...  
Keyword(s):  
Risk Factors ◽  
Logistic Regression ◽  
Regression Analysis ◽  
Malignant Melanoma ◽  
Logistic Regression Analysis ◽  
Case Control Study ◽  
Case Control ◽  
Melanoma Risk ◽  
Anatomic Site ◽  
Control Study

Sensitivity and Specificity of Self-examination for Cutaneous Malignant Melanoma Risk Factors

1993 ◽  
Vol 9 (1) ◽  
pp. 50-54 ◽  
Author(s):  
Stephen B. Gruber ◽  
George C. Roush ◽  
Raymond L. Barnhill
Keyword(s):  
Risk Factors ◽  
Malignant Melanoma ◽  
Sensitivity And Specificity ◽  
Cutaneous Malignant Melanoma ◽  
Melanoma Risk ◽  
Self Examination

scholarly journals Public awareness of malignant melanoma risk factors in Germany.

1997 ◽  
Vol 51 (6) ◽  
pp. 698-700 ◽  
Author(s):  
A Pfahlberg ◽  
O Gefeller ◽  
K F Kolmel
Keyword(s):  
Risk Factors ◽  
Malignant Melanoma ◽  
Public Awareness ◽  
Melanoma Risk

scholarly journals Prevalence of nevi, atypical nevi, and lentigines in relation to tobacco smoking

PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0254772
Author(s):  
Birgit Sadoghi ◽  
Karin Schmid-Zalaudek ◽  
Iris Zalaudek ◽  
Regina Fink-Puches ◽  
Anna Niederkorn ◽  
...  
Keyword(s):  
Risk Factors ◽  
Malignant Melanoma ◽  
Tobacco Use ◽  
Tobacco Smoking ◽  
Melanoma Risk ◽  
Skin Examination ◽  
Exogenous Factors ◽  
Total Body ◽  
Atypical Nevi ◽  
Age And Sex

Background Melanocytic nevi have a complex evolution influenced by several endogenous and exogenous factors and are known risk factors for malignant melanoma. Interestingly, tobacco use seems to be inversely associated with melanoma risk. However, the association between tobacco use and nevi and lentigines has not yet been evaluated. Methods We investigated the prevalence of nevi, atypical nevi, and lentigines in relation to tobacco smoking in a cohort of 59 smokers and 60 age- and sex-matched nonsmokers, using a questionnaire and performing a total body skin examination by experts. Results No significant differences were detected between smokers and nonsmokers in the numbers of nevi, atypical nevi, and lentigines in sun-exposed areas (p = 0.966, 0.326, and 0.241, respectively) and in non-sun-exposed areas (p = 0.095, 0.351, and 0.546, respectively). Conclusion Our results revealed no significant differences in the prevalence of nevi, atypical nevi, and lentigines between smokers and nonsmokers in sun-exposed and non-sun-exposed areas.

scholarly journals Parkinson’s Disease as a Risk Factor for Melanoma: A Review

2021 ◽  
Vol 5 (5) ◽  
pp. 503-511
Author(s):  
Zachary Monahan ◽  
Aaron Cantor ◽  
Kent Handfield
Keyword(s):  
Risk Factors ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Malignant Melanoma ◽  
Subsequent Development ◽  
Disease Diagnosis ◽  
Melanoma Risk ◽  
Estimated Risk ◽  
Meta Analyses ◽  
Relationship Of

Objective: To review the literature and place into a quantified context the relationship of Parkinson’s disease diagnosis to a subsequent diagnosis of malignant melanoma, and to briefly explore potential molecular associations between the two diseases. Methods: The Medline database was queried with terms related to Parkinson’s disease (PD) and malignant melanoma, with use of Boolean operator AND to identify studies involving both diseases. Studies were divided into primary and meta-analyses, with exclusive evaluation of those quantifying risk of malignant melanoma after an established diagnosis of Parkinson’s disease. Critical studies were identified using Medline searches to identify established quantified risk metrics between classic melanoma risk factors and subsequent development of malignant melanoma. Results: Twelve primary studies and three meta-analyses were evaluated and their risk metrices tabulated. Three studies offered estimated risk of development of malignant melanoma in patients with classic melanoma risk factors. These metrices were also tabulated and compared with the metrices established by the twelve primary studies. This demonstrated a similarity in overall risk of developing malignant melanoma in a patient with a diagnosis of Parkinson’s disease as compared to a patient with classical melanoma risk factors. Limitations: Relatively few studies identified specifically quantified the classic risk factors for melanoma, and relatively few studies specifically quantified the degree of risk for developing melanoma after an established Parkinson’s disease diagnosis. Conclusion: It is wise to consider the presence of Parkinson’s disease in a patient as one factor when clinicians decide on the appropriateness of regular full body screening examinations.

Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study

2008 ◽  
Vol 19 (7) ◽  
pp. 759-765 ◽  
Author(s):  
Charlotte Gerd Hannibal ◽  
Allan Jensen ◽  
Heidi Sharif ◽  
Susanne Krüger Kjaer
Keyword(s):  
Cohort Study ◽  
Malignant Melanoma ◽  
Melanoma Risk ◽  
Fertility Drugs ◽  
Danish Cohort

scholarly journals Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis

2020 ◽  
Vol 63 (3) ◽  
pp. 101-112
Author(s):  
Fatemeh Asadian ◽  
Seyed Mohammadreza Niktabar ◽  
Yaser Ghelmani ◽  
Shadi Kargar ◽  
Elahe Akbarian ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Meta Analysis ◽  
Complementation Group ◽  
Cutaneous Malignant Melanoma ◽  
Case Control Studies ◽  
Melanoma Risk ◽  
Pooled Data ◽  
Increased Risk ◽  
Pcr Rflp ◽  
Rflp Assay

Background: A number of studies have reported that the xeroderma pigmentosum complementation group C (XPC) polymorphisms are associated with cutaneous malignant melanoma (CMM) susceptibility. But the results of those studies were inconsistent. Here, we performed a study to obtain a more conclusive result on the association of XPC polymorphisms with risk of CMM. Methods: The XPC Lys939Gln and Ala499Val polymorphisms were genotyped in 150 CMM cases and 150 controls by PCR-RFLP assay. Subsequently, all published relevant studies were identified through a comprehensive literature search in PubMed, Web of Science, and CNKI databases. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of correlation. Results: There was no significant association between XPC Lys939Gln and Ala499Val polymorphisms and CMM risk in our population. A total of 15 case-control studies including ten studies with 5,990 cases and 7,697 controls on XPC Lys939Gln and five studies with 3,139 cases and 3,721 controls on XPC Ala499Val polymorphism were selected. Pooled data revealed that XPC Lys939Gln (C vs. A: OR = 1.108, 95% CI 1.008– 1.217; P = 0.033) and Ala499Val (C vs. A: OR = 0.918, 95% CI 0.850–0.992; p = 0.031; CC+CA vs. AA: OR = 0.904, 95% CI 0.819–0.997; p = 0.043) polymorphisms were significantly associated with an increased risk of CMM. Moreover, stratified analyses by ethnicity revealed that the XPC Ala499Val and Lys939Gln polymorphisms were significantly associated with risk of CMM in Caucasians and mixed populations, respectively. Conclusions: This meta-analysis result suggested that XPC Lys939Gln and Ala499Val polymorphisms were significantly associated with risk of CMM.

Sign in / Sign up

Export Citation Format

Share Document